1. Home
  2. RENX vs ONCO Comparison

RENX vs ONCO Comparison

Compare RENX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$0.13

Market Cap

2.0M

Sector

N/A

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.76

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RENX
ONCO
Founded
2021
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
2.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RENX
ONCO
Price
$0.13
$0.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.1M
229.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,524,116.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4217.31
52 Week Low
$0.11
$0.05
52 Week High
$0.35
$7.65

Technical Indicators

Market Signals
Indicator
RENX
ONCO
Relative Strength Index (RSI) 41.22 36.81
Support Level N/A $0.62
Resistance Level $0.17 $1.87
Average True Range (ATR) 0.04 0.17
MACD -0.00 -0.00
Stochastic Oscillator 2.52 8.30

Price Performance

Historical Comparison
RENX
ONCO

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: